[go: up one dir, main page]

HUP0103346A2 - Készítmény és eljárás péniszerekció diszfunkció kezelésére - Google Patents

Készítmény és eljárás péniszerekció diszfunkció kezelésére

Info

Publication number
HUP0103346A2
HUP0103346A2 HU0103346A HUP0103346A HUP0103346A2 HU P0103346 A2 HUP0103346 A2 HU P0103346A2 HU 0103346 A HU0103346 A HU 0103346A HU P0103346 A HUP0103346 A HU P0103346A HU P0103346 A2 HUP0103346 A2 HU P0103346A2
Authority
HU
Hungary
Prior art keywords
composition
mixture
amount
erectile dysfunction
components
Prior art date
Application number
HU0103346A
Other languages
English (en)
Inventor
Robert J. Gyurik
Scott F. Krauser
Carlos M. Samour
Original Assignee
Macrochem Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Macrochem Corporation filed Critical Macrochem Corporation
Publication of HUP0103346A2 publication Critical patent/HUP0103346A2/hu
Publication of HUP0103346A3 publication Critical patent/HUP0103346A3/hu
Publication of HU224318B1 publication Critical patent/HU224318B1/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Gynecology & Obstetrics (AREA)
  • Inorganic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Beans For Foods Or Fodder (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

A találmány tárgya készítmény helyi alkalmazásra olyan személyekpéniszére, akiknek erre szükségük van, amely készítmény (a)prosztaglandin E1 farmakológiailag hatásos mennyiségét; (b) egy C6-C20szénhidrogéncsoporttal helyettesített 1,3-dioxánokból, 1,3-dioxolánokból és acetálokból álló csoportból kiválasztott,bőrbehatolást fokozó vegyület behatolást fokozó mennyiségét; (c) egygyógyszerészetileg hatékony vivőanyagot, amely (i) etilalkohol és víz,az (a) és (b) komponenseket szolubilizáló keveréke; (ii)izopropilalkohol és víz, az (a) és (b) komponenseket szolubilizálókeveréke; vagy (iii) egy olyan keverék lehet, amely az etilalkohol,izopropilalkohol közül legalább egyet és propilénglikolt tartalmaz; és(d) egy sűrítőszer sűrítő hatású mennyiségét; és adott esetben (e)mentol irritáció ellen hatékony mennyiségét tartalmazza. Ó
HU0103346A 1998-06-15 1998-06-15 Készítmény és eljárás péniszerekció diszfunkció kezelésére HU224318B1 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US1998/012284 WO1999065303A1 (en) 1998-06-15 1998-06-15 Composition and method for treating penile erectile dysfunction

Publications (3)

Publication Number Publication Date
HUP0103346A2 true HUP0103346A2 (hu) 2002-01-28
HUP0103346A3 HUP0103346A3 (en) 2004-06-28
HU224318B1 HU224318B1 (hu) 2005-07-28

Family

ID=22267309

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0103346A HU224318B1 (hu) 1998-06-15 1998-06-15 Készítmény és eljárás péniszerekció diszfunkció kezelésére

Country Status (18)

Country Link
US (1) US5942545A (hu)
EP (1) EP1026947B1 (hu)
JP (1) JP3513764B2 (hu)
KR (1) KR20010022296A (hu)
CN (1) CN1206998C (hu)
AT (1) ATE209856T1 (hu)
AU (1) AU764437B2 (hu)
BR (1) BR9811797A (hu)
CA (1) CA2296373C (hu)
DE (1) DE69802838T2 (hu)
DK (1) DK1026947T3 (hu)
ES (1) ES2170503T3 (hu)
HK (1) HK1030133A1 (hu)
HU (1) HU224318B1 (hu)
IL (1) IL134191A0 (hu)
NO (1) NO20000157L (hu)
PL (1) PL189436B1 (hu)
WO (1) WO1999065303A1 (hu)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6251436B1 (en) 1995-09-29 2001-06-26 L.A.M. Pharmaceutical Corporation Drug preparations for treating sexual dysfunction
GR1002847B (el) 1997-05-06 1998-01-27 Χρηση της μισοπροστολης ή/και της μισοπροστολης οξυ για την παρασκευη φαρμακευτικου προιοντος για τη θεραπευτικη αντιμετωπιση των δυσλειτουργιων της στυσεως
US6414028B1 (en) * 1997-11-05 2002-07-02 Nexmed Holdings, Inc. Topical compositions containing prostaglandin E1
GR1003199B (el) 1998-08-14 1999-09-01 Χρηση της μισοπροστολης ή και της μισοπροστολης οξυ για την παρασκευη φαρμακευτικου προιοντος για τη θεραπευτικη αντιμετωπιση της σεξουαλικης δυσλειτουργιας στις γυναικες
FR2789586A1 (fr) * 1999-02-16 2000-08-18 Synthelabo Composition pharmaceutique pour administration transmucosale balanique d'alfuzosine
WO2000051978A1 (en) 1999-03-01 2000-09-08 Nitromed, Inc. Nitrosated and nitrosylated prostaglandins, compositions and metods of use
CN1350521A (zh) 1999-03-05 2002-05-22 宝洁公司 C16不饱和的fp选择性前列腺素类似物
AU5957600A (en) * 1999-07-30 2001-02-19 Lakefield Minerals Ltd. Pharmaceutical compositions for topical application to treat erectile dysfunction
US6894175B1 (en) 1999-08-04 2005-05-17 The Procter & Gamble Company 2-Decarboxy-2-phosphinico prostaglandin derivatives and methods for their preparation and use
US6730065B1 (en) * 2000-09-15 2004-05-04 Ocularis Pharma, Inc. Night vision composition
US6582683B2 (en) 2000-01-04 2003-06-24 Skinvisible Pharmaceuticals, Inc. Dermal barrier composition
US7105571B2 (en) * 2000-01-10 2006-09-12 Nexmed Holdings, Inc. Prostaglandin compositions and methods of treatment for male erectile dysfunction
US6323241B1 (en) 2000-01-10 2001-11-27 Nexmed (Holdings) Inc. Prostaglandin compositions and methods of treatment for male erectile dysfunction
US6693135B2 (en) * 2000-01-10 2004-02-17 Nexmed (Holdings) Incorporated Prostaglandin compositions and methods of treatment for male erectile dysfunction
US20020037914A1 (en) 2000-03-31 2002-03-28 Delong Mitchell Anthony Compositions and methods for treating hair loss using C16-C20 aromatic tetrahydro prostaglandins
US20020172693A1 (en) 2000-03-31 2002-11-21 Delong Michell Anthony Compositions and methods for treating hair loss using non-naturally occurring prostaglandins
US20020013294A1 (en) 2000-03-31 2002-01-31 Delong Mitchell Anthony Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives
KR100402334B1 (ko) * 2000-06-23 2003-10-22 환인제약 주식회사 알프로스타딜 외용제
WO2002007757A2 (en) 2000-07-21 2002-01-31 Lue Tom F Prevention and treatment of sexual arousal disorders
US7223406B2 (en) * 2000-07-21 2007-05-29 The Regents Of The University Of California Methods and compositions for preventing and treating male erectile dysfunction and female sexual arousal disorder
CA2416709A1 (en) * 2000-07-31 2003-01-17 Ono Pharmaceutical Co., Ltd. Therapeutic agent for erectile dysfunction containing as the active ingredient prostaglandin derivatives
US6503894B1 (en) 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
US20030139384A1 (en) * 2000-08-30 2003-07-24 Dudley Robert E. Method for treating erectile dysfunction and increasing libido in men
KR100649860B1 (ko) * 2000-09-01 2006-11-24 주식회사종근당 알프로스타딜 경점막 및 경피흡수제제
KR20020020536A (ko) * 2000-09-09 2002-03-15 장우영 발기유발제
KR100373540B1 (ko) * 2000-09-20 2003-02-25 최한곤 프로스타글란딘 ｅ1용 요도좌제 조성물
US20060211753A1 (en) * 2000-11-03 2006-09-21 Ocularis Pharma, Inc. Method and composition which reduces stimulation of muscles which dilate the eye
CN100581544C (zh) * 2001-03-05 2010-01-20 美国医疗产品公司 用于勃起机能障碍治疗和逆转的可注射药物组合物
HU225597B1 (en) * 2001-03-30 2007-05-02 Futura Medical Dev Ltd Condom with an erectogenic compound or composition and use of an erectogenic compound or composition for the manufacture of a medicament and use of an erectogenic compound for preparation of a composition
US20030138494A1 (en) * 2001-05-15 2003-07-24 L.A.M. Pharmaceutical Corporation Drug preparations for treating sexual dysfunction
US7244703B2 (en) * 2001-06-22 2007-07-17 Bentley Pharmaceuticals, Inc. Pharmaceutical compositions and methods for peptide treatment
US6756059B2 (en) * 2001-08-20 2004-06-29 Skinvisible Pharmaceuticals, Inc. Topical composition, topical composition precursor, and methods for manufacturing and using
US7041305B2 (en) * 2001-09-07 2006-05-09 Western Holdings, Llc Stable water in oil aminophylline emulsions
KR100446960B1 (ko) * 2001-12-04 2004-09-01 김종국 프로스타글란딘 ｅ1을 포함하는 온도감응성 에멀젼 외용제조성물
KR100810404B1 (ko) * 2001-12-18 2008-03-04 환인제약 주식회사 알프로스타딜 알킬 에스테르를 함유하는 외용제 조성물
US6673841B2 (en) 2001-12-20 2004-01-06 Whan In Pharm. Co., Ltd. Alprostadil alkyl ester-containing composition for external application
BR0307345A (pt) * 2002-02-15 2004-12-14 Nexmed Holdings Inc Métodos para tratar disfunção erétil, para melhorar a microcirculação da glans penis e para produzir intumescência da glans penis em um paciente necessitando de tais tratamentos, artigo de manufatura, e, composição
US6919348B2 (en) * 2002-05-02 2005-07-19 Edward T. Wei Therapeutic 1,2,3,6-tetrahydropyrimidine-2-one compositions and methods therewith
US20030219696A1 (en) * 2002-05-23 2003-11-27 Moreland Gerald W. Method and apparatus for preventing backflow in dental saliva evacuators
GB0222522D0 (en) 2002-09-27 2002-11-06 Controlled Therapeutics Sct Water-swellable polymers
US20040126339A1 (en) * 2002-12-31 2004-07-01 Roszell James A. Sunscreen composition and methods for manufacturing and using a sunscreen composition
US20050181030A1 (en) * 2003-01-03 2005-08-18 Mo Y. J. Topical stabilized prostaglandin E compound dosage forms
US6841574B2 (en) * 2003-01-03 2005-01-11 Nexmed Holdings, Inc. Topical stabilized prostaglandin E compound dosage forms
MXPA05009816A (es) 2003-03-21 2005-12-05 Nexmed Holdings Inc Composiciones y metodos para el tratamiento de la eyaculacion precoz.
AU2004224459A1 (en) * 2003-03-21 2004-10-07 Nexmed (Holdings), Inc. Angiogenesis promotion by prostaglandin compositions and methods
AU2004227853A1 (en) * 2003-04-02 2004-10-21 Nexmed (Holdings), Inc. Prostaglandin compositions and their use for the treatment of vasospasm
US20050049311A1 (en) * 2003-09-03 2005-03-03 Pharmacia & Upjohn Company Medicinal products comprising prostaglandin compositions and methods of packaging such compositions
KR100978717B1 (ko) 2003-12-08 2010-08-30 씨펙스 파마슈티칼스, 인코포레이티드 인슐린 치료를 위한 약제 조성물 및 방법
GB0417401D0 (en) 2004-08-05 2004-09-08 Controlled Therapeutics Sct Stabilised prostaglandin composition
US20060127483A1 (en) * 2004-12-10 2006-06-15 Alan Drizen Topical drug delivery system
PT3456329T (pt) 2005-10-12 2025-02-25 Besins Healthcare Lu Sarl Gel de testosterona melhorado e método de utilização
GB0613333D0 (en) 2006-07-05 2006-08-16 Controlled Therapeutics Sct Hydrophilic polyurethane compositions
GB0613638D0 (en) 2006-07-08 2006-08-16 Controlled Therapeutics Sct Polyurethane elastomers
US7560489B2 (en) * 2006-10-11 2009-07-14 Nexmed Holdings, Inc. Stabilized prostaglandin E composition
GB0620685D0 (en) 2006-10-18 2006-11-29 Controlled Therapeutics Sct Bioresorbable polymers
US20100137333A1 (en) * 2006-10-20 2010-06-03 Roszell James A Antifungal composition and methods for using
US9005183B2 (en) * 2007-05-16 2015-04-14 Health Knight, Llc System and method for treating erectile dysfunction
US8128913B1 (en) 2007-12-06 2012-03-06 Skinvisible Pharmaceuticals, Inc. Sunscreen composition with enhanced UV-A absorber stability and methods
BRPI0800596A2 (pt) 2008-01-31 2009-09-22 Univ Minas Gerais método para a potencialização da função erétil através do uso das composições farmacêuticas de toxina tx2-6 da aranha phoneutria nigriventer
US8299122B2 (en) * 2008-04-14 2012-10-30 Skinvisible Pharmaceuticals, Inc. Method for stabilizing retinoic acid, retinoic acid containing composition, and method of using a retinoic acid containing composition
JP2014510156A (ja) 2011-04-07 2014-04-24 ネクスメッド ホールディングス，インコーポレイテッド レイノー病を治療する方法および組成物
PT3934624T (pt) * 2019-12-09 2024-04-23 Futura Medical Developments Ltd Composição tópica e métodos de medição da capacidade de arrefecimento de uma composição tópica
CA3074150A1 (en) 2020-02-18 2021-08-18 Ovation Science, Inc. Composition and method for transdermal delivery of cannabidiol (cbd) and delta9-tetrahydrocannabinol (thc)
US12053479B2 (en) 2020-10-22 2024-08-06 Madera Pharm aceuticals, Inc. Transdermal treatment for erectile dysfunction

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4127118B1 (en) * 1977-03-16 1995-12-19 Alvaro Latorre Method of effecting and enhancing an erection
US4311707A (en) * 1979-02-12 1982-01-19 American Cyanamid Company Process for topically producing cutaneous vasodilation for the treatment of vasospastic or ischemic conditions
US4861764A (en) * 1986-11-17 1989-08-29 Macro Chem. Corp. Percutaneous absorption enhancers, compositions containing same and method of use
US5219885A (en) * 1987-02-16 1993-06-15 Froelich Juergen Prostaglandin E1 derivatives as pharmaceutically active agents, and pharmaceutical compositions containing these compounds, especially for transcutaneous administration
US4801587A (en) * 1987-03-02 1989-01-31 Gene Voss Impotence ointment
US5256652A (en) * 1987-11-12 1993-10-26 Pharmedic Co. Topical compositions and methods for treatment of male impotence
SE463851B (sv) * 1988-09-02 1991-02-04 Amsu Ltd Komposition foer behandling av erektil dysfunktion via uretra
AU616571B2 (en) * 1988-10-28 1991-10-31 Shiseido Company Ltd. Cosmetic composition containing inclusion product with hydroxyalkylated cyclodextrin
US5059603A (en) * 1989-06-12 1991-10-22 Centuries Laboratories, Inc. Method and composition for treating impotence
FR2649613B1 (fr) * 1989-07-11 1991-09-27 Virag Ronald Medicament vaso-actif
US5236904A (en) * 1989-09-18 1993-08-17 Senetek, Plc Erection-inducing methods and compositions
IT1252603B (it) * 1990-04-19 1995-06-19 Giorgio Cavallini 2,4-diamino-6 piperidino pirimidina-3 ossido topico sul glande nel trattamento delle impotenze erettili
US5242391A (en) * 1990-04-25 1993-09-07 Alza Corporation Urethral insert for treatment of erectile dysfunction
US5270323A (en) * 1990-05-31 1993-12-14 Pfizer Inc. Method of treating impotence
IT1247678B (it) * 1990-05-31 1994-12-28 Alberto Reale Metodo per la cura dell'impotenza erettiva maschile
US5399581A (en) * 1990-12-26 1995-03-21 Laragh; John H. Method and compositions for treatment of sexual impotence
DE4117249C2 (de) * 1991-05-27 1998-05-14 Christian Dr Stief Linsidomin zur Behandlung erektiler Dysfunktionen
KR940703666A (ko) * 1991-12-23 1994-12-12 로렌스 티. 웰츠 발기 부전증 치료에 효능있는 약제(a potent drug for treatment of erectile dysfunction)
ATE169826T1 (de) * 1992-01-21 1998-09-15 Macrochem Corp Iontophoretische verbesserte verabreichung von medikamenten
US5400094A (en) * 1993-03-31 1995-03-21 Minnesota Mining And Manufacturing Company Condensers for overhead projectors
US5439938A (en) * 1993-04-07 1995-08-08 The Johns Hopkins University Treatments for male sexual dysfunction
US5565466A (en) * 1993-08-13 1996-10-15 Zonagen, Inc. Methods for modulating the human sexual response
US5587167A (en) * 1993-09-14 1996-12-24 Choi; Hyung K. Pharmaceutical composition for prophylaxis and treatment of premature ejaculation
US5380760A (en) * 1993-11-19 1995-01-10 Minnesota Mining And Manufacturing Company Transdermal prostaglandin composition
US5482039A (en) * 1994-03-25 1996-01-09 Vivus, Inc. Process for diagnosing erectile dysfunction, and related methods of treatment
US5451609A (en) * 1994-07-27 1995-09-19 Institut De Recherches Chimiques Et Al Treatment of impotence
US5594032A (en) * 1994-11-10 1997-01-14 Gonzalez-Cadavid; Nestor F. Amelioration of human erectile dysfunction by treatment with iNOS, inducers of iNOS or iNOS cDNA
US5620980A (en) * 1995-02-22 1997-04-15 Macrochem Corporation Method for treating hair loss
US5583144A (en) * 1995-02-24 1996-12-10 Kral; John G. Methods for treating erectile impotence
US5968919A (en) * 1997-10-16 1999-10-19 Macrochem Corporation Hormone replacement therapy drug formulations for topical application to the skin

Also Published As

Publication number Publication date
US5942545A (en) 1999-08-24
ES2170503T3 (es) 2002-08-01
CN1206998C (zh) 2005-06-22
DE69802838T2 (de) 2002-06-27
AU7838798A (en) 2000-01-05
JP2000511944A (ja) 2000-09-12
WO1999065303A1 (en) 1999-12-23
CN1267191A (zh) 2000-09-20
NO20000157L (no) 2000-02-09
DK1026947T3 (da) 2002-04-02
CA2296373C (en) 2003-08-12
ATE209856T1 (de) 2001-12-15
JP3513764B2 (ja) 2004-03-31
PL189436B1 (pl) 2005-08-31
NO20000157D0 (no) 2000-01-12
IL134191A0 (en) 2001-04-30
HUP0103346A3 (en) 2004-06-28
KR20010022296A (ko) 2001-03-15
BR9811797A (pt) 2000-09-26
HU224318B1 (hu) 2005-07-28
HK1030133A1 (en) 2001-04-27
AU764437B2 (en) 2003-08-21
PL338787A1 (en) 2000-11-20
EP1026947B1 (en) 2001-12-05
EP1026947A1 (en) 2000-08-16
CA2296373A1 (en) 1999-12-23
DE69802838D1 (de) 2002-01-17
EP1026947A4 (en) 2000-10-25

Similar Documents

Publication Publication Date Title
HUP0103346A2 (hu) Készítmény és eljárás péniszerekció diszfunkció kezelésére
ES2141950T3 (es) Composiciones que contienen troxerutina complejada con fosfatidilcolina para el tratamiento topico de la impotencia erectil.
HUP0004350A2 (hu) Vegyületek női szexuális diszfunkció kezelésére
EE200100176A (et) Fentanüüli kasutamine farmatseutilise kompositsiooni valmistamiseks, mis on ette nähtud akuutse valu raviks, ning farmatseutiline kompositsioon
GEP20063982B (en) Use of prostaglandin compositions with male persons for treatment of erectile dysfunction
DK0880350T3 (da) Behandling af dissemineret sklerose
CY1105931T1 (el) Χρηση ενος αγωνιστη/ανταγωνιστη οιστρογονου για την αντιμετωπιση γυναικειας σεξουαλικης δυσλειτουργιας
BRPI0006634B8 (pt) composição tópica compreendendo extrato de matricária no tratamento e prevenção de distúrbios inflamatórios
DK1137409T3 (da) Præparater og fremgangsmåde til lindring af human kvindelig seksuel dysfunktion
BR9509807A (pt) Composição líquida para administração oral e processo para tratar um mamífero incluindo o homem que esteja sofrendo de um quadro clinico mediado pela aç o do 5ht nos receptores 5ht3
DK0526566T3 (da) Behandling af erektil dysfunktion
EA200400007A1 (ru) ФАРМАЦЕВТИЧЕСКИЙ СОСТАВ ДЛЯ ЭФФЕКТИВНОГО ВВЕДЕНИЯ АПОМОРФИНА, 6aR-(-)-N-ПРОПИЛ-НОРАПОМОРФИНА, ИХ ПРОИЗВОДНЫХ И ИХ ПРОЛЕКАРСТВ
HUP0102728A2 (hu) Módszerek és transzdermális készítmények fájdalom csillapítására
AR043660A1 (es) El tratamiento de la enfermedad de alzheimer
CY1108631T1 (el) Μεθοδοι και συνθεσεις για τη θεραπεια στυτικης δυσλειτουργιας των ανδρων
WO1999019304A3 (en) Alpha-alkylthio substituted pyrimidine ethers and thioethers as viral reverse transcriptase inhibitors
AR019327A1 (es) Combinacion de fentolamina y apomorfina para el tratamiento de la funcion y disfuncion sexual humana
HUP0203050A2 (hu) Endometriózis és meddőség kezelésére, valamint a termékenység fokozására alkalmas gyógyszerkészítmények
ES2169942T3 (es) Uso de preparaciones topicas de trinitrato de glicerilo y lanolina para el tratamiento de la disfuncion erectil.
MXPA04002050A (es) Composicion farmaceutica comprendiendo gamma-butirobetaina.
HUP9900601A2 (hu) Benzopirán-származékok allograftkilökődés megelőzésére
ES2089669T3 (es) Utilizacion de los derivados de isoquinolinona en el tratamiento de la hiperlipoproteinemia.
ECSP993026A (es) Combinacion de fentolamina y apomorfina para el tratamiento de la funcion y disfuncion sexual humana

Legal Events

Date Code Title Description
HFG4 Patent granted, date of granting

Effective date: 20050613

MM4A Lapse of definitive patent protection due to non-payment of fees